Cogito, ergo sum, as the phrase goes in Latin, cemented the way the Western world would continue to define the self for the ...

Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA).

What if Teresa of Ávila (1515–1582)—whose body is on public display for the first time in 110 years—influenced René Descartes ...

Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...

This study is being conducted to evaluate the safety, tolerability, and ability to manufacture Descartes-08, an investigational mRNA CAR-T cell therapy, in people living with moderate to severe ...